Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) today announced positive results from the Phase 2 PREVENT study. PREVENT is a multi-center ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments Trading Halts

Eiger BioPharmaceuticals (EIGR) to Resume Trading at 4:35 pm ETOctober 16, 2018 4:28 PM Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)October 16, 2018 4:05 PM Eiger BioPharmaceuticals (EIGR) Halted, News PendingOctober 16, 2018 4:03 PM